Study: NCT00074490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m(2)/day intravenous (IV), day 1 (for cluster of differentiation 20 (CD20+) patients).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide: 50 mg/m(2)/day continuous intravenous (CIV), days 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin:10 mg/m(2)/day continuous intravenous (CIV), days 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine: 0.4 mg/m(2)/day continuous intravenous (CIV), days 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell (PBSC) transplantation
Description: PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell (PBSC) transplantation
Description: PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell (PBSC) transplantation
Description: PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell (PBSC) transplantation
Description: PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell (PBSC) transplantation
Description: PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell (PBSC) transplantation
Description: PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
Description: The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
Description: The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
Description: The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
Description: The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone: 60 mg/m(2)/day by mouth (PO), days 1-5.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplant (HSCT)
Description: Allogeneic Hematopoietic Stem Cell Transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplant (HSCT)
Description: Allogeneic Hematopoietic Stem Cell Transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplant (HSCT)
Description: Allogeneic Hematopoietic Stem Cell Transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplant (HSCT)
Description: Allogeneic Hematopoietic Stem Cell Transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplant (HSCT)
Description: Allogeneic Hematopoietic Stem Cell Transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplant (HSCT)
Description: Allogeneic Hematopoietic Stem Cell Transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) \> 1000, two values; or ANC \> 5000 cells/ul on one occasion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) \> 1000, two values; or ANC \> 5000 cells/ul on one occasion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) \> 1000, two values; or ANC \> 5000 cells/ul on one occasion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) \> 1000, two values; or ANC \> 5000 cells/ul on one occasion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) \> 1000, two values; or ANC \> 5000 cells/ul on one occasion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) \> 1000, two values; or ANC \> 5000 cells/ul on one occasion).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T-Rapa cell Donor Lymphocyte Infusion (DLI)
Description: The dose of T helper 2 (Th2) cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) Th2/kg; minimum dose will be 1 x 10(7) Th2/kg).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T-Rapa cell Donor Lymphocyte Infusion (DLI)
Description: The dose of T helper 2 (Th2) cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) Th2/kg; minimum dose will be 1 x 10(7) Th2/kg).